SOUTH SAN FRANCISCO, Calif. (PRWEB)
October 11, 2022

Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced a collaboration agreement with Visikol® for service offerings using Imaging Mass Cytometry™.

The agreement is an expansion of the relationship established in 2020 under which Visikol will offer IMC services to clients from its site in Hampton, NJ. Visikol, a contract research services company focused on advanced tissue imaging and advanced cell culture assays, services all 20 of the top pharmaceutical companies. Visikol will leverage the Standard BioTools™ Hyperion+™ Imaging System, based on Imaging Mass Cytometry (IMC™), in its multiplex tissue imaging services. This initiative is supported by Visikol’s digital pathology services, which aim to transform large imaging-based datasets into actionable insights.

Recently, the demand for tools to evaluate the complex immune cell landscape has grown dramatically as researchers, biotech companies, and pharmaceutical companies look to develop immuno-oncology therapeutics and better understand the intricate interplay between the immune system and disease.

Multiplex tissue imaging is a key tool that researchers can use to characterize a wide range of immune cell and tissue-specific biomarkers simultaneously. Standard BioTools has developed a version of this technology, IMC that currently allows for 40-plus markers to be detected on a single slide with an unprecedented level of sensitivity, quantification, and absence of autofluorescence. In addition, IMC’s rapid panel design capability is particularly well suited to applications within contract research organizations.

“As a company that is focused on advanced tissue imaging, we are excited to add IMC to our portfolio of tools and to work closely with Standard BioTools, as it will allow us to better meet the needs of our clients,” said Visikol CEO Michael Johnson, PhD. “IMC provides our clients with the unique ability to image many markers simultaneously while providing an unparalleled level of image quality.”

“IMC is one of the essential technologies that Standard BioTools provides,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “The valuable relationship with Visikol broadens the use of IMC for spatial omics studies, offering a vital tool in the acceleration of drug discovery and development in particular when dealing with precious and scarce patient biopsies. We look forward to working with the Visikol team to help their pharma clients uncover important spatial relationships within the tissue microenvironment.”

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the potential benefits of research conducted using Standard BioTools products and technologies and anticipated benefits to Standard BioTools of an expanded collaboration. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to interruptions or delays in the supply of components or materials for, or manufacturing of, Standard BioTools products; potential product performance and quality issues; intellectual property risks; competition; uncertainties in contractual relationships; and reductions in research and development spending or changes in budget priorities by customers. Information on these and additional risks and uncertainties and other information affecting Standard BioTools’ business and operating results is contained in its Annual Report on Form 10-K for the year ended December 31, 2021, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Standard BioTools disclaims any obligation to update these forward-looking statements except as may be required by law.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm, is driven by a bold purpose –Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.  Learn more at http://www.standardbio.com or connect with us on Twitter®, Facebook®, LinkedIn, and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, “Unleashing tools to accelerate breakthroughs in human health,” CyTOF, Hyperion, Hyperion+, Imaging Mass Cytometry and IMC are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

About Visikol

Visikol is a contract research services company that is focused on accelerating the drug discovery and development process through providing its clients with advanced tissue imaging and advanced cell culture services. Today, Visikol counts the top 20 pharmaceutical companies as clients and has been instrumental in dozens of drug discovery programs. The company provides end-to-end services that include 3D tissue imaging, multiplex tissue imaging, digital pathology, high-content imaging, 2D cell culture assays, 3D cell culture assays, and ex vivo tissue slice assays. Visikol’s expertise lies in both transforming tissues into actionable insights and bridging the gap between in vitro assays and in vivo results through the use of best in-class cell culture models. In addition to its services, Visikol sells a suite of tissue clearing reagents and kits as well as the HUREL® Micro Liver portfolio of primary hepatocyte liver models. Learn more at http://www.visikol.com.

Available Information

Standard BioTools uses its website (standardbio.com), investor site (investors.standardbio.com), corporate Twitter account (@Standard_BioT), Facebook page (facebook.com/StandardBioT), and LinkedIn page (linkedin.com/company/standard-biotools) as channels of distribution of information about its products, its planned financial and other announcements, its attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and Standard BioTools may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Standard BioTools’ website and its social media accounts in addition to following its press releases, SEC filings, public conference calls, and webcasts.

Investors:

Peter DeNardo

415 389 6400

ir@standardbio.com

Source: Standard BioTools Inc.

Share article on social media or email:

WORTHINGTON, Ohio (PRWEB)
October 11, 2022

MedVet has opportunities for aspiring emergency medicine veterinarians in the class of 2023 to receive a scholarship, signing bonus, and guaranteed position in MedVet’s profession-leading Emergency Clinician Mentorship Program (ECMP) after graduation.

Candidates who sign at an eligible location by Dec. 31, 2022, will receive a $15,000 scholarship for their last semester of veterinary school (amount not to exceed the total for tuition and fees). They’ll also receive a signing bonus of up to $35,000 which varies by location. Eligible hospital locations include Akron (OH), Asheville (NC), Cincinnati (OH), Chicago (IL), Diley Hill (OH), Indianapolis (IN), Lexington (KY), Mobile (AL), Norwalk (CT), Pittsburgh (PA), and Toledo (OH).

“This is an opportunity for veterinary students to receive substantial financial support to wrap up veterinary school while also jump-starting a fulfilling career in emergency medicine after graduation with the team that is Leading Specialty Healthcare for Pets,” said Dr. Jon Fletcher, Director of Post-Graduate Medical Education at MedVet.

Following graduation, accepted candidates will join MedVet as ECMP doctors. The ECMP is an accelerated training program that allows new veterinarians to enhance their diagnostic and therapeutic capabilities, advance clinical decision-making and technical skills, and hone their communication. At the center of the program is a mentor-mentee relationship that ensures a smooth transition into emergency medicine.

“The ECMP is the premier training program for developing ER veterinarians. They are entrusted with all the duties of an emergency veterinarian, but with their mentor by their side, they are never left alone or lost in the shuffle. This program is tailor-made to fit the unique needs and goals of the mentee and, as a result, they show unbelievable clinical growth,” explained Dr. Mackenzie Ruehl, Medical Director at MedVet Hilliard and ECMP Training Director.

To apply, veterinary students in their final year of veterinary school should contact Amanda Purcell at Amanda.purcell@medvet.com or 614.368.2568. Candidates can also learn more about MedVet and the ECMP on medvet.com.

About MedVet:

MedVet is the leading veterinarian owned and led family of specialty and emergency hospitals dedicated to delivering exceptional care and a deeply supportive experience to pets and their loving families, referring veterinarians, and team members. For more than 30 years, MedVet’s empathetic, insightful, and driven team of expert caregivers has helped the organization grow to be the preferred choice for high quality, compassionate care, proudly serving more than 500,000 patients each year in communities throughout the United States. To learn more about MedVet and its mission of Leading Specialty Healthcare for Pets, visit medvet.com. 

###

Share article on social media or email:

BOSTON (PRWEB)
October 11, 2022

Activate Care®, a leader in social risk management solutions, today announced a partnership with Kronos Health. The primary healthcare provider based in Lawrence, MA has begun offering Activate Care’s Path Assist, a proactive model that addresses a person’s SDOH-driven needs and navigates them through an intervention with a Community Health Navigator to improve patient outcomes and lower costs of care.

By driving action upstream, Path Assist takes a whole-person approach to care interventions – a departure from the traditional model that retroactively responds to healthcare events, such as a visit to the emergency room triggered by a lack of shelter.

“I believe we need to redesign primary health care delivery to better serve the needs of all patients,” said Dr. Scott Early, founder of Kronos Health. “By deploying Activate Care’s Path Assist, we are taking a proactive approach to the factors that impact a person’s health, such as housing, food security and transportation, in order to better address the whole patient and drive better health outcomes and improve people’s quality of life.”

How it Works

Path Assist is available to all patients within Kronos Health’s community. Once enrolled, patients are assigned a Community Health Navigator (CHN) who listens to their needs, helps create goals, connects them to local resources and services and coaches them to improve health confidence.

To take advantage of the program, people need to follow four easy steps:

● Sign up online or ask their provider

● Complete a screening to help understand each individual’s needs

● Connect with a CHN virtually or physically each week

● Receive up to three months of services

“For too long, we have taken a very narrow view of healthcare – that it’s what happens when a person is in the office,” said Activate Care’s CEO and Co-Founder, Ted Quinn. “But that is not always helping people how, when and where they need it. As more healthcare providers integrate SDOH into their care delivery models, we will begin to see real change in patients’ health outcomes, satisfaction and trust in the healthcare system – and the amount we’re collectively spending on healthcare. Taking a whole-person approach to care, like Kronos Health, is a win for everyone.”

To connect with Activate Care to learn how Path Assist can address SDOH in your community, visit: https://path-assist.com/client-howitworks/.

About Activate Care®

At Activate Care, we’re on a mission to improve health equity and drive improved health outcomes across the country. We do this by providing direct support to individuals navigating social health challenges. Our locally-hired workforce is trained to engage and empower individuals using best practices while leveraging secure, accessible technology. Our goal is simple: improve poor outcomes and reduce high cost due to Social Determinants of Health. We are confident of the potential of our solution, Path Assist, to positively impact the health of communities with an effective, efficient, and measurable model which is locally responsive and nationally scalable.

For more information, visit https://www.activatecare.com.

About Kronos Health

Kronos Health is an innovative primary care practice serving the Merrimack Valley in Massachusetts. The aim of Kronos Health is to provide better care to patients by building a comprehensive and proactive model of care. Kronos Health fundamentally re-designs how health care is delivered, especially in underserved communities. Kronos Health believes that providing sufficient time to do a good job will improve the quality of care, decrease waste and improve the satisfaction of patients and the professionals who care for them.

For more information, visit https://www.kronoshealth.com/.

Share article on social media or email:

CHARLOTTE, N.C. (PRWEB)
October 11, 2022

Reproductive Specialists of the Carolinas (“RSC”) is pleased to announce that Dr. Luwam Ghidei, an award-winning reproductive endocrinologist and infertility specialist, has joined the boutique fertility practice, making it possible for even more patients to receive advanced and inclusive reproductive care.

Dr. Ghidei has the training and experience to diagnose and treat all infertility causes, with a specific interest in recurrent pregnancy loss, infertility, fibroids, polycystic ovarian syndrome, fertility preservation, third-party reproduction, and resolving healthcare disparities. She received her medical degree from the University of Texas Southwestern Medical School before completing an Obstetrics and Gynecology residency at Brown University/Women and Infants Hospital in Providence, Rhode Island. She completed her fellowship in Reproductive Endocrinology and Infertility, as well as a Master of Science in clinical investigation at Baylor College of Medicine.

In addition to her impressive background and training, Dr. Ghidei has also won numerous awards, including most recently the President’s Presenter Award from the Society for Reproductive Investigation, and has published many studies in peer-reviewed journals to further advance reproductive medicine and optimize patient experiences.

As a passionate supporter of equal rights for everyone, Dr. Ghidei is committed to honoring the pillars of inclusivity and advocacy that define the RSC practice. “It is my goal and privilege to provide each of my patients with compassionate and respectful care, while helping them achieve their individualized reproductive goals,” she says.

Dr. Johnson said: “I am so grateful to have a new, young, intelligent, and passionate REI join our team at RSC! With Dr. Ghidei’ s passion and modern outlook on fertility care, I know that our patients and staff alike will undoubtedly benefit with her addition to the team. Welcome to RSC, Dr. Ghidei!”

The addition of Dr. Ghidei to the staff comes on the heels of a practice relocation earlier this year. The new 11,000-square-foot facility in Charlotte, NC includes a state-of-the-art IVF laboratory, and further enhances treatment offerings for patients, which include intrauterine insemination (IUI), infertility assessments, oncofertility, in vitro fertilization (IVF), egg freezing, and more.

Reproductive Specialists of the Carolinas is located at 1918 Randolph Rd, Ste 410, Charlotte, NC 28207-1109. To learn more, please email info@fertilitycarolinas.com or call to schedule an appointment to see Dr. Ghidei at (704) 247-2209.

Share article on social media or email:

NEW YORK (PRWEB)
October 11, 2022

atria health announced today that it has entered into a long-term partnership with leading independent physician practice AMS Cardiology (AMS) in Montgomery County, PA. This first-of-its-kind partnership expands upon atria’s efforts to empower community cardiologists to transform how care is delivered and paid for nationally.

“We are excited about the opportunity to partner with atria to improve access to comprehensive, integrated care for our patients,” said Adam Cohen, MD, Managing Partner of AMS Cardiology. “atria’s unique operating model allows our practice to remain truly independent while supporting us with the resources necessary to accelerate growth and clinical innovation in our market.”

“Legacy models for treating and paying for cardiac care have failed to innovate and put patients first,” said Scott Shapiro, MD, AMS cardiologist and Chief Strategy Officer at The Physicians Integrated Network (TPIN). “Partnering with atria reinforces our patient-centric and physician-driven philosophy and delivers the resources and expertise necessary to serve the individual needs of our patients through a sustainable, quality-focused approach.”

The company also announced the appointment of experienced industry executive Matt Eakins, MD to its Board of Directors.

Dr. Eakins serves as the Chief Innovation Officer of Unified Women’s Healthcare, a diversified women’s health company supporting over 2,500 providers across more than 900 locations. He leads the Diversified Business Group, which was created to find and grow strategic partnerships with payor organizations and other community-based healthcare providers seeking to improve quality and health outcomes for patients. Previously, Dr. Eakins was Chief Operating Officer for Unified and Senior Vice President of Operations. Prior to joining Unified, Dr. Eakins was a management consultant at McKinsey & Company, advising clients across the healthcare value chain.

“We are delighted to welcome Matt to our Board as an independent director,” said Dr. Cohen. “He has been instrumental in the formation of atria and brings a wealth of experience in healthcare innovation, most notably in building high performing provider organizations and pioneering the implementation of alternative payment models.”

About atria health

atria health is a physician-owned practice support organization. The company enables a network of high-performing, community-based heart specialists to redefine the role of the physician in cardiac care. For more information, please visit http://www.atriahealth.co.

About AMS Cardiology

Founded in 1970, AMS Cardiology is a leading provider of high-quality cardiovascular disease care in the Greater Philadelphia Area, offering a comprehensive array of services, including general clinical cardiology, preventive cardiology and dyslipidemia management, cardio-oncology, cardio-obstetrics, echocardiography and nuclear cardiology, interventional cardiology, peripheral vascular disease, electrophysiology, valvular and structural heart disease. For more information, please visit http://www.amscardiology.com.

Share article on social media or email: